Skip to main content
OpenTrials
Completed

NCT Number: NCT00765817

Addition Of Exenatide To Insulin Glargine In Type 2 Diabetes Mellitus

This study will compare the efficacy and safety of exenatide versus placebo in adults whose diabetes is not fully controlled by insulin glargine with or without metformin and/or pioglitazone.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Type 2 Diabetes Diabetes Mellitus Diabetes Mellitus, Type 2 Endocrine System Diseases Glucose Metabolism Disorders Metabolic Diseases Nutritional and Metabolic Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Research Site, Athens, Greece

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Have type 2 diabetes.
  • Have been taking insulin glargine at a dose of ≥20 units/day for at least 3 months before entering the study.

Have been taking insulin glargine alone or in combination with one of the following for at least 3 months before entering the study:

  • metformin (stable dose for 6 weeks)
  • pioglitazone (stable dose for 6 weeks)
  • a combination of metformin and pioglitazone (stable dose for 6 weeks)
  • Have HbA1C between 7.1% and 10.5%, inclusive.
  • Have a body mass index (BMI) ≤45 kg/m2.
  • Have a history of stable body weight (not varying by >5% for at least 3 months prior to screening).

Exclusion criteria

  • Have taken medications to lower blood sugar other than insulin glargine, pioglitazone, or metformin in the 3 months before entering the study for more than a 1-week period, or within 1 week of entering the study.
  • Have had more than one episode of major (severe) hypoglycemia in the 6 months before entering the study.
  • Are pregnant or intend to become pregnant during the study or are sexually active women not actively practicing birth control.
  • Women who are breastfeeding.
  • Have any significant diseases of the blood, heart, kidney, gastrointestinal system, or other significant diseases such as cancer.
  • Have had a kidney transplant or are currently on kidney dialysis.
  • Have a cancer that's never been treated, that's currently being treated, or that was diagnosed within the last 5 years.
  • Have had a bad reaction to exenatide in the past or have a condition that is not recommended to be exposed to exenatide or any of exenatide's other ingredients.
  • Have used a drug for weight loss in the 3 months before entering the study for more than a 1-week period, or within 1 month of entering the study.
  • Are currently on a weight-loss program or have been on one within 3 months of entering the study.
  • Have had a blood transfusion or severe blood loss within 3 months of entering the study.
  • Are taking systemic glucocorticoids or have received systemic glucocorticoids within 8 weeks of entering the study.
  • Have an irregular sleep cycle (for example, sleeping during the day and working during the night).
  • Have a history of pancreatitis.
  • Have received treatment with an experimental drug within 30 days of entering the study.
  • If on metformin, have a condition that is not recommended to be exposed to metformin, or any condition associated with hypoperfusion, hypoxemia, dehydration, or sepsis.
  • If on metformin, have had a radiologic contrast study performed within 48 hours of entering the study.
  • If on pioglitazone, have a condition that is not recommended to be exposed to pioglitazone, including congestive heart failure, or are taking pioglitazone at a dose that is not approved for use with insulin.

Treatment and study plan

Placebo

Drug

subcutaneous injection, twice a day

exenatide

Drug

subcutaneous injection, twice a day, 10mcg

Primary outcomes

  1. Change in Glycosylated Hemoglobin (HbA1c)

    Time frame: baseline and 30 weeks

    Change in HbA1c from baseline following 30 weeks of therapy (i.e., HbA1c at week 30 minus HbA1c at baseline). Unit of measure is percent of hemoglobin that is glycosylated.

Secondary outcomes

  1. Percentage of Patients Achieving HbA1c <=7%

    Time frame: baseline and 30 weeks

    Percentage of patients in each arm who had HbA1c >7% at baseline and had HbA1c <=7% at week 30 (percentage = [number of subjects with HbA1c <=7% at week 30 divided by number of subjects with HbA1c >7% at baseline] * 100%).

  2. Percentage of Patients Achieving HbA1c <=6.5%

    Time frame: baseline and 30 weeks

    Percentage of patients in each arm who had HbA1c >6.5% at baseline and had HbA1c <=6.5% at week 30 (percentage = [number of subjects with HbA1c <=6.5% at week 30 divided by number of subjects with HbA1c >6.5% at baseline] * 100%).

  3. Change in Fasting Serum Glucose

    Time frame: baseline and 30 weeks

    Change in fasting serum glucose following 30 weeks of therapy (i.e., fasting serum glucose at week 30 minus fasting serum glucose at baseline)

  4. Change in 7-point Self-monitored Blood Glucose (SMBG) Profile

    Time frame: baseline and 30 weeks

    Change in 7-point (pre-breakfast, 2 hour post-breakfast, pre-lunch, 2 hour post-lunch, pre-dinner, 2 hour post-dinner, 0300 hours) SMBG profile from baseline to week 30 (change = blood glucose value at week 30 minus blood glucose value at baseline)

  5. Change in Total Cholesterol

    Time frame: baseline and 30 weeks

    Change in total cholesterol following 30 weeks of therapy (i.e., total cholesterol at week 30 minus total cholesterol at baseline)

  6. Change in Low Density Lipoprotein (LDL) Cholesterol

    Time frame: baseline and 30 weeks

    Change in LDL cholesterol following 30 weeks of therapy (i.e., LDL cholesterol at week 30 minus LDL cholesterol at baseline)

  7. Change in High Density Lipoprotein (HDL) Cholesterol

    Time frame: baseline and 30 weeks

    Change in HDL cholesterol following 30 weeks of therapy (i.e., HDL cholesterol at week 30 minus HDL cholesterol at baseline)

  8. Change in Triglycerides

    Time frame: baseline and 30 weeks

    Change in triglycerides following 30 weeks of therapy (i.e., triglycerides at week 30 minus triglycerides at baseline)

  9. Change in Body Weight

    Time frame: baseline and 30 weeks

    Change in body weight following 30 weeks of therapy (i.e., body weight at week 30 minus body weight at baseline)

  10. Change in Waist Circumference

    Time frame: baseline and 30 weeks

    Change in waist circumference following 30 weeks of therapy (i.e., waist circumference at week 30 minus waist circumference at baseline)

  11. Change in Daily Insulin Dose

    Time frame: baseline and 30 weeks

    Change in daily insulin dose following 30 weeks of therapy (i.e., daily insulin dose at week 30 minus daily insulin dose at baseline)

  12. Change in Daily Insulin Dose (on a Per Body Weight Basis)

    Time frame: baseline and 30 weeks

    Change in daily insulin dose per kilogram (kg) following 30 weeks of therapy (i.e., daily insulin dose per kg at week 30 minus daily insulin dose per kg at baseline)

  13. Change in Systolic Blood Pressure (SBP)

    Time frame: baseline and 30 weeks

    Change in SBP following 30 weeks of therapy (i.e., SBP at week 30 minus SBP at baseline)

  14. Change in Diastolic Blood Pressure (DBP)

    Time frame: baseline and 30 weeks

    Change in DBP following 30 weeks of therapy (i.e., DBP at week 30 minus DBP at baseline)

  15. Minor Hypoglycemia Rate Per Year

    Time frame: baseline and weeks 2, 4, 6, 8, 10, 14, 18, 22, 26, and 30

    Number of minor hypoglycemia events experienced per subject per year. Minor hypoglycemia was defined as any time a subject felt he or she was experiencing a sign or symptom associated with hypoglycemia that was either self-treated by the subject or resolved on its own and had a concurrent finger stick blood glucose <3.0 mmol/L (54 mg/dL).

  16. Percentage of Subjects Experiencing Minor Hypoglycemia

    Time frame: baseline and weeks 2, 4, 6, 8, 10, 14, 18, 22, 26, and 30

    Percentage of subjects in each arm experiencing at least one episode of minor hypoglycemia at any point during the study. Minor hypoglycemia was defined as any time a subject felt he or she was experiencing a sign or symptom associated with hypoglycemia that was either self-treated by the subject or resolved on its own and had a concurrent finger stick blood glucose <3.0 mmol/L (54 mg/dL).

Sponsors and collaborators

Lead sponsor

AstraZeneca

Industry

Collaborators

  • Eli Lilly and Company

Registry information

Official study title

A Randomized Trial Comparing Exenatide With Placebo in Subjects With Type 2 Diabetes on Insulin Glargine With or Without Oral Antihyperglycemic Medications

Important dates

Study start
2008
Primary completion
2010
Study completion
2010
First posted
Oct 3, 2008
Registry last updated
Oct 24, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.